Table 1 Oncologic outcomes after radical trachelectomy (where N > 100 reported)
Study | Eligible for fertility sparing (N) | Stage (N) | Histology (N) | LVSI+ (N) | Approach | LN+ (N) | Required adjuvant therapy (N) | Successful fertility sparing (N) | Primary recurrences (N) (mos) | Dead of disease (N) (mos) | Median follow up months (range) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Shepherd 2006 [108] | 123 | IA2 = 2 IB1 = 121 | 83 SCC 33 AC 3 AS 4 other | 39 | VRT | 7 | 11 | 112 | 5 (15, 19, 21, 31, 84) | 4 (26, 26, 32, 32) | 45a (1–120) |
Marchiole 2007 [109] | 118 | IA1 = 10 IA2 = 19 IB1 = 83 IIA = 6 | 90 SCC 25 AC/AS 3 rare | 43 | LAVRT | 5 | 8 | 97 | 7 (7, 11, 18, 19, 20, 21, 93) | 5 (21, 24, 26, 27. 41) | 95 (31–234) |
Plante 2011 [57] | 140 | IA1 = 7 IA2 = 30 IB1 = 97 IB2 = 3 IIA = 3 | 78 SCC 52 AC 10 AS | 40 | VRT | 5 | 15 | 110 | 6 (−) | 2 (−) | 95 (4–225) |
Helpman 2011 [35] | 140 | All IA-IB | 74 AC 66 SCC | 55 | VRT | 8 | 9 | 140 | 8 (−) | 0 | 60 (−) |
Wethington 2012 [110] | 101 | IA1 = 3 IA2 = 8 IB1 = 88 IB2 = 1 IIA = 1 | 40 SCC 6 AS 54 AC 1 clear cell | 47 | ART | 19 | 20 | 70 | 4 (−) | 0 | 32 (1–124) |
Cao 2013 [51] | 150 | 18 IA1 19 IA2 113 IB1 | 135 SCC 15 AC | 8 | VRT ART | 0 | 0 | 150 | 7 (−) | 2 (−) | 25 (6–91) |
Mangler 2014 [111] | 320¥ | IA1 = 46 IA2 = 68 IB2 = 207 | 220 SCC 97 AC 5 AS | 94 | VRT | – | – | 320 | 10 (mean 26.1 month, range 3–108) | 5 (16, 19, 22, 29, 30) | 48 (0–216) |
Hauerberg 2015 [112] | 120 | CIS = 2 IA1 = 7 IA2 = 8 IB1 = 103 | 82 SCC 36 AC 2 AS | 30 | VRT | 4 | 12 | 108 | 6 (−) | 2 (−) | 55.7 (5.5–147) |
Vieira 2015 [113] | 100 | IA1 = 6 IA2 = 25 IB1 = 69 | 49 SCC 42 AC 7 AS 2 mixed | 25 | ART RRT LRT | 2 | 9 | 83 | 0 | 0 | 51 (10–147) |
Total | N = 1312 |  |  |  |  |  |  | N = 1190 | N = 53 | N = 20 |  |
Crude rates (%) |  |  |  |  |  |  |  |  | Recurrence rate = 4.5 %# | Mortality rate = 1.7 %# |  |